Davion Healthcare
DAVI on Nasdaq. Surgical & medical instruments & apparatus. Market value $30m.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
What to watch out for
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.
$1.68 a share, at its 1-year low
Over the past year the price has ranged from $1.65 to $12.30.
Price from Friday’s close (30 October).
Five years of cash, in billions
Five-year fundamentals are not available yet.
Health checks
- Free cash flow positiveNot enough data
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)Not enough data
- DebtUnknown
- Revenue growth, five yearsUnknown
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 30 April 2026
- Next quarterly (estimated, 10-Q)
- n/a
Who owns it
We don't have fund holdings for this stock yet.
Big holders and activists
1 investor owns more than 5%.
- JACK HARRY KAYEInsider or founder34.7%−6.4 ptsSince 19 November 2026
What they said
On November 19, 2026, the Reporting Person transferred an aggregate of 1,600,000 ordinary shares of the Issuer by way of four separate bona fide gifts to four individuals. The transfers were made without consideration and were not undertaken in connection with any sale,…
Read the filing - RALLINSON LTDInsider or founderSold down below 5%Since 11 August 2026
What they said
On August 11, 2026, Rallinson Corp transferred 1,245,000 Ordinary Shares of the Issuer to Jack Harry Kaye for no consideration, and Rallinson Ltd transferred 3,860,530 Ordinary Shares of the Issuer to Mr. Kaye for no consideration. Mr. Kaye is the sole director, sole shareholder…
Read the filing
| Holder | Stake | Since | |
|---|---|---|---|
JACK HARRY KAYE Insider or founder | 34.7%−6.4 pts | 19 November 2026 | What they saidOn November 19, 2026, the Reporting Person transferred an aggregate of 1,600,000 ordinary shares of the Issuer by way of four separate bona fide gifts to four individuals. The transfers were made without consideration and were not undertaken in connection with any sale,… Read the filing |
RALLINSON LTD Insider or founder | Sold down below 5% | 11 August 2026 | What they saidOn August 11, 2026, Rallinson Corp transferred 1,245,000 Ordinary Shares of the Issuer to Jack Harry Kaye for no consideration, and Rallinson Ltd transferred 3,860,530 Ordinary Shares of the Issuer to Mr. Kaye for no consideration. Mr. Kaye is the sole director, sole shareholder… Read the filing |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 2 insiders bought $36,290 of shares on the open market.
- King Susan MDirectorBought
- Date
- 17 November 2026
- Shares
- 10,000
- Price
- $0.98
- Value
- $9,800
- Sluyters JulianDirectorBought
- Date
- 16 November 2026
- Shares
- 25,000
- Price
- $1.06
- Value
- $26,490
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 17 November 2026 | King Susan M Director | Bought | 10,000 | $0.98 | $9,800 |
| 16 November 2026 | Sluyters Julian Director | Bought | 25,000 | $1.06 | $26,490 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
Davion Healthcare doesn’t file a US annual report (10-K), so we haven’t checked it.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.